The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.

Tag:

Pfizer

Latest Headlines

Latest Headlines

Pfizer to acquire GlaxoSmithKline meningitis vaccines for $130M

In a move to allay antitrust concerns, GlaxoSmithKline is selling two of its meningitis vaccines to Big Pharma peer Pfizer. The move comes after Glaxo acquired the bulk of Novartis' vaccines portfolio, which catapulted it to the No. 1 spot in the global vaccines market.

Pfizer's Lipset plots path to mainstream acceptance of experimental trial techs

Almost exactly four years after Pfizer wowed the clinical trial sector with its plans for a virtual, fully-remote study, one of the people behind the project has outlined how the industry is continuing to move the methods it pioneered toward the mainstream.

Merck, GSK, Sanofi and Pfizer will vie for crown in tight vaccines race by 2020: Report

Anyone expecting one vaccines maker to pull away from the pack by 2020 had better reconsider. The top four companies--Merck, GlaxoSmithKline, Sanofi and Pfizer--are expected to be within less than one percentage point of each other in total market share, a new report says.

Pharma ad budgets to dip in 2016, but J&J, Pfizer, Roche and Novartis should still top $2B

Flat news is good news. Pharma spending on advertising and promotional expenses will dip by just 1.7% next year, according to Schonfeld & Associates' annual Advertising Ratios & Budgets. That means a total of more than $21 billion in ad spending and just a bit healthier than last year's decline of 2%.

Deal buzz: Forget Pfizer. Traders bet GSK as a match for J&J, Roche

Another week, another rumor about the target on GlaxoSmithKline's back. This time, U.K. traders were talking up a different potential takeover--not by Pfizer, but by Johnson & Johnson or Roche.

Pfizer supplements its China production with $90M plant

Pfizer has broken ground on a $90 million facility that is being built in Suzhou, China, it announced Monday. The additional capacity is needed as demand for its supplements grows in the Asia-Pacific region, particularly in China.

Takeda taps Sanford for robotics, 3-D modeling skills in heart failure pact

Sanford-Burnham Medical Research Institute is about to apply its robotics and 3-D modeling skills to the discovery of molecules to treat heart failure. Takeda is bankrolling the two-year program as part of its broader collaboration The Sanford Consortium for Regenerative Medicine.

Pfizer's Pristiq antidepressant comes up short for kids

When the FDA approved Wyeth's antidepressant Pristiq in 2008, the nod came with a number of provisions to do postmarketing studies, including one in pediatric patients. Seven years later, Pfizer, which bought Wyeth in a 2009 megamerger, has fulfilled that obligation to disappointing results. The drug failed to hit its endpoint.

Pfizer in quick succession turns aside second lawsuit alleging Zoloft birth defects ties

Just weeks after winning the first case to go to trial that accused Pfizer of hiding birth defect risks for the children of women who took the antidepressant Zoloft during pregnancy, the pharma giant has again convinced a jury that there was no credible connection. The results are positive for Pfizer, but the company still faces more than 1,000 lawsuits alleging similar claims.

Inflectra vs. Remicade study could be just what the doctor ordered for biosimilars

A study released today that pitted Hospira's biosimilar Inflectra against its reference drug Remicade in patients with rheumatoid arthritis is good news for Hospira, and by default Pfizer. It found that patients who were switched to the copy did just as well, with no unexpected side effects, as they had on Merck and Johnson & Johnson's Remicade.